Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 8/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 8/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25225173 | 0.92 | CSNK1E (0.43) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL24553908 | 0.91 | CSNK1E (0.43) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL29683158 | 0.91 | CSNK1E (0.43) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL25227728 | 0.90 | CSNK1E (0.50) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL25224457 | 0.90 | CSNK1E (0.42) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL25221371 | 0.89 | CSNK1E (0.45) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL25221877 | 0.88 | CSNK1E (0.45) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL28875913 | 0.88 | CSNK1E (0.42) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 | |
| SCHEMBL24553853 | 0.87 | CSNK1E (0.51) | CSNK1ECSNK1DGRIA1CACNG2 | |
| SCHEMBL24553808 | 0.87 | CSNK1E (0.46) | CSNK1ECSNK1DKCNK3GRIA1CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4126878-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | CSNK1E 9/4885CSNK1D 10/4885KCNK3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.